Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
Y-mAbs Therapeutics, Inc. (YMAB)
|
Add to portfolio |
|
|
|
| Price: |
$16.52
| | Metrics |
| OS: |
43.6
|
M
| |
|
|
| Market cap: |
$721
|
M
| |
|
|
|
Net cash:
|
$87.9
|
M
| |
$2.02
|
per share
|
|
EV:
|
$633
|
M
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
|
| |
|
|
|
EBIT
|
|
| |
|
|
| EPS |
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-21 | Dec-31-20 | Mar-31-20 | Dec-31-19 | Mar-31-19 | Dec-31-18 | Dec-31-17 | Dec-31-16 |
| Revenues | 34.9 | 20.8 | 18.6 | 0.0 | 12.5 | 0.0 | 0.0 | 13.9 |
| Revenue growth | 68.2% | | 48.8% | | | | -100.0% | |
| Cost of goods sold | 2.3 | 2.2 | 26.7 | 0.0 | 16.3 | 0.0 | 0.0 | 17.0 |
| Gross profit | 32.6 | 18.5 | -8.1 | 0.0 | -3.7 | 0.0 | 0.0 | -3.2 |
| Gross margin | 93.4% | 89.4% | -43.6% | | -29.9% | | | -23.0% |
| Selling, general and administrative | 54.6 | 44.8 | | 19.5 | | | | |
| Research and development | 93.2 | 93.7 | | 63.5 | | 34.3 | 14.3 | |
| General and administrative | | | 8.1 | | 3.7 | 9.0 | 4.9 | 3.2 |
| EBIT | -53.4 | -119.9 | -26.7 | -83.0 | -16.3 | -43.2 | -19.2 | -17.0 |
| EBIT margin | -153.1% | -578.0% | -143.6% | | -129.9% | | | -123.0% |
| Pre-tax income | -55.3 | -119.3 | -26.2 | -81.0 | -15.9 | -43.3 | -19.2 | -17.1 |
| Income taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | -55.3 | -119.3 | -26.2 | -81.0 | -15.9 | -43.3 | -19.2 | 0.0 |
| Net margin | -158.4% | -575.1% | -140.6% | | -127.4% | | | -0.1% |
| |
| Diluted EPS | ($1.28) | ($2.97) | ($0.66) | ($2.30) | ($0.47) | ($1.50) | ($0.99) | ($1.21) |
| Shares outstanding (diluted) | 43.2 | 40.1 | 39.8 | 35.2 | 34.2 | 28.8 | 19.4 | 0.0 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|